Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.53 |
| ▸ | NAAA | Q02083 | 11/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698470 | 0.89 | EPHX1 (0.46) | EPHX1SMN1; SMN2FKBP1ANAAA | |
| SCHEMBL4463802 | 0.89 | EPHX1 (0.57) | EPHX1SMN1; SMN2FKBP1ANAAA | |
| SCHEMBL696982 | 0.87 | EPHX1 (0.44) | EPHX1SMN1; SMN2FKBP1ANAAA | |
| SCHEMBL4476050 | 0.87 | EPHX1 (0.54) | EPHX1SMN1; SMN2FKBP1ANAAA | |
| SCHEMBL698517 | 0.83 | EPHX1 (0.40) | EPHX1SMN1; SMN2FKBP1ANAAA | |
| SCHEMBL2906497 | 0.82 | EPHX1 (0.51) | EPHX1SMN1; SMN2FKBP1ANAAA | |
| SCHEMBL6931991 | 0.81 | SMN1; SMN2 (0.56) | EPHX1SMN1; SMN2FKBP1ANAAA | |
| SCHEMBL19842292 | 0.81 | SMN1; SMN2 (0.56) | EPHX1SMN1; SMN2FKBP1ANAAA | |
| SCHEMBL13686651 | 0.80 | SMN1; SMN2 (0.51) | EPHX1SMN1; SMN2FKBP1ANAAA | |
| SCHEMBL8944571 | 0.79 | EPHX1 (0.56) | EPHX1SMN1; SMN2FKBP1ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217564-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2009033054-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | EPHX1 3143/4885SMN1; SMN2 385/4885FKBP1A 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.